These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 39062921)

  • 1. HIPK2 in Colon Cancer: A Potential Biomarker for Tumor Progression and Response to Therapies.
    Verdina A; Garufi A; D'Orazi V; D'Orazi G
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39062921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear factor erythroid 2 (NF-E2) p45-related factor 2 interferes with homeodomain-interacting protein kinase 2/p53 activity to impair solid tumors chemosensitivity.
    D'Orazi G; Garufi A; Cirone M
    IUBMB Life; 2020 Aug; 72(8):1634-1639. PubMed ID: 32593231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIPK2 role in the tumor-host interaction: Impact on fibroblasts transdifferentiation CAF-like.
    Garufi A; Traversi G; Cirone M; D'Orazi G
    IUBMB Life; 2019 Dec; 71(12):2055-2061. PubMed ID: 31414572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucose restriction induces cell death in parental but not in homeodomain-interacting protein kinase 2-depleted RKO colon cancer cells: molecular mechanisms and implications for tumor therapy.
    Garufi A; Ricci A; Trisciuoglio D; Iorio E; Carpinelli G; Pistritto G; Cirone M; D'Orazi G
    Cell Death Dis; 2013 May; 4(5):e639. PubMed ID: 23703384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIPK2-a therapeutical target to be (re)activated for tumor suppression: role in p53 activation and HIF-1α inhibition.
    Nardinocchi L; Puca R; Givol D; D'Orazi G
    Cell Cycle; 2010 Apr; 9(7):1270-5. PubMed ID: 20234185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis.
    Nardinocchi L; Puca R; Sacchi A; D'Orazi G
    Mol Cancer; 2009 Jan; 8():1. PubMed ID: 19128456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updates on HIPK2: a resourceful oncosuppressor for clearing cancer.
    D'Orazi G; Rinaldo C; Soddu S
    J Exp Clin Cancer Res; 2012 Aug; 31(1):63. PubMed ID: 22889244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homeodomain-interacting protein kinase 2 (HIPK2): a promising target for anti-cancer therapies.
    Feng Y; Zhou L; Sun X; Li Q
    Oncotarget; 2017 Mar; 8(12):20452-20461. PubMed ID: 28107201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting hypoxia in cancer cells by restoring homeodomain interacting protein-kinase 2 and p53 activity and suppressing HIF-1alpha.
    Nardinocchi L; Puca R; Sacchi A; Rechavi G; Givol D; D'Orazi G
    PLoS One; 2009 Aug; 4(8):e6819. PubMed ID: 19714248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivation of homeodomain-interacting protein kinase 2 promotes oral squamous cell carcinoma metastasis through inhibition of P53-dependent E-cadherin expression.
    Zheng X; Pan Y; Chen X; Xia S; Hu Y; Zhou Y; Zhang J
    Cancer Sci; 2021 Jan; 112(1):117-132. PubMed ID: 33063904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIPK2 is a potential predictive marker of a favorable response for adjuvant chemotherapy in stage II colorectal cancer.
    Verdina A; Di Segni M; Amoreo CA; Sperduti I; Buglioni S; Mottolese M; Di Rocco G; Soddu S
    Oncol Rep; 2021 Mar; 45(3):899-910. PubMed ID: 33650652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown.
    Puca R; Nardinocchi L; Gal H; Rechavi G; Amariglio N; Domany E; Notterman DA; Scarsella M; Leonetti C; Sacchi A; Blandino G; Givol D; D'Orazi G
    Cancer Res; 2008 May; 68(10):3707-14. PubMed ID: 18483253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting COX-2/PGE(2) pathway in HIPK2 knockdown cancer cells: impact on dendritic cell maturation.
    Garufi A; Pistritto G; Ceci C; Di Renzo L; Santarelli R; Faggioni A; Cirone M; D'Orazi G
    PLoS One; 2012; 7(11):e48342. PubMed ID: 23144866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperglycemia triggers HIPK2 protein degradation.
    Baldari S; Garufi A; Granato M; Cuomo L; Pistritto G; Cirone M; D'Orazi G
    Oncotarget; 2017 Jan; 8(1):1190-1203. PubMed ID: 27901482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIPK2 in cancer biology and therapy: Recent findings and future perspectives.
    Conte A; Valente V; Paladino S; Pierantoni GM
    Cell Signal; 2023 Jan; 101():110491. PubMed ID: 36241057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homeodomain-interacting protein kinase-2 restrains cytosolic phospholipase A2-dependent prostaglandin E2 generation in human colorectal cancer cells.
    D'Orazi G; Sciulli MG; Di Stefano V; Riccioni S; Frattini M; Falcioni R; Bertario L; Sacchi A; Patrignani P
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):735-41. PubMed ID: 16467083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression.
    Bon G; Di Carlo SE; Folgiero V; Avetrani P; Lazzari C; D'Orazi G; Brizzi MF; Sacchi A; Soddu S; Blandino G; Mottolese M; Falcioni R
    Cancer Res; 2009 Jul; 69(14):5978-86. PubMed ID: 19567674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Tyrosine Kinase c-Abl Promotes Homeodomain-interacting Protein Kinase 2 (HIPK2) Accumulation and Activation in Response to DNA Damage.
    Reuven N; Adler J; Porat Z; Polonio-Vallon T; Hofmann TG; Shaul Y
    J Biol Chem; 2015 Jul; 290(27):16478-88. PubMed ID: 25944899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIPK2 suppresses tumor growth and progression of hepatocellular carcinoma through promoting the degradation of HIF-1α.
    Chen P; Duan X; Li X; Li J; Ba Q; Wang H
    Oncogene; 2020 Apr; 39(14):2863-2876. PubMed ID: 32034309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homeodomain-interacting protein kinase 2 (HIPK2) targets beta-catenin for phosphorylation and proteasomal degradation.
    Kim EA; Kim JE; Sung KS; Choi DW; Lee BJ; Choi CY
    Biochem Biophys Res Commun; 2010 Apr; 394(4):966-71. PubMed ID: 20307497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.